📊 SERA Key Takeaways
Is Sera Prognostics, Inc.. (SERA) a Good Investment?
SERA is a pre-revenue/near-zero revenue company burning approximately $8.8M in cash quarterly with only $4.2M in cash reserves, implying less than 2 months of operational runway. Despite a healthy balance sheet with $67.6M equity and minimal debt, the company's fundamental inability to generate meaningful revenue combined with massive operating losses creates an imminent solvency crisis requiring immediate capital infusion or business transformation.
Sera Prognostics, Inc.. Key Strengths (SERA)
- Zero financial leverage (no long-term debt; Debt/Equity 0.00x)
- Positive stockholders' equity of $67.6M provides theoretical liquidation cushion
- Loss metrics trending positively YoY (net loss improved 2.9% despite lack of scale)
SERA Stock Risks: Sera Prognostics, Inc.. Investment Risks
- Catastrophic cash runway: $4.2M cash versus $8.8M quarterly cash burn implies insolvency within 6 weeks
- Negligible revenue generation ($14K quarterly) fails to offset any operating costs; unsustainable business model
- 21 Form 4 filings in 90 days suggests elevated insider activity, potentially indicating management awareness of distress and opportunistic selling
- Operating losses of $9.4M on $14K revenue demonstrates complete absence of path to profitability
- Imminent capital raise requirement will create severe shareholder dilution
Key Metrics to Watch
- Quarterly cash balance and monthly burn rate
- Revenue growth trajectory and customer acquisition metrics
- Capital raise announcements and dilution impact
- Insider transaction volumes and direction (buying vs selling)
- Time to next cash requirement/runway remaining
Sera Prognostics, Inc.. (SERA) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 2.12x current ratio provides a solid financial cushion.
SERA Profit Margin, ROE & Profitability Analysis
SERA vs Healthcare Sector: How Sera Prognostics, Inc.. Compares
How Sera Prognostics, Inc.. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Sera Prognostics, Inc.. Stock Overvalued? SERA Valuation Analysis 2026
Based on fundamental analysis, Sera Prognostics, Inc.. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Sera Prognostics, Inc.. Balance Sheet: SERA Debt, Cash & Liquidity
SERA Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Sera Prognostics, Inc..'s revenue has remained relatively flat over the 5-year period, with a 1% decline. The most recent EPS of $-0.99 indicates the company is currently unprofitable.
SERA Revenue Growth, EPS Growth & YoY Performance
SERA Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $14.0K | -$8.2M | $-0.17 |
| Q3 2025 | $16.0K | -$7.8M | $-0.16 |
| Q2 2025 | $17.0K | -$8.0M | $-0.16 |
| Q1 2025 | N/A | -$8.1M | $-0.20 |
| Q3 2024 | $29.0K | -$7.2M | $-0.23 |
| Q2 2024 | $24.0K | -$8.1M | $-0.25 |
| Q1 2024 | N/A | -$8.1M | $-0.25 |
| Q3 2023 | $42.0K | -$7.2M | $-0.23 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Sera Prognostics, Inc.. Dividends, Buybacks & Capital Allocation
SERA SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Sera Prognostics, Inc.. (CIK: 0001534969)
📋 Recent SEC Filings
❓ Frequently Asked Questions about SERA
What is the AI rating for SERA?
Sera Prognostics, Inc.. (SERA) has an AI grade of D with 95% confidence, based on fundamental analysis of SEC EDGAR filings.
What are SERA's key strengths?
Claude: Zero financial leverage (no long-term debt; Debt/Equity 0.00x). Positive stockholders' equity of $67.6M provides theoretical liquidation cushion.
What are the risks of investing in SERA?
Claude: Catastrophic cash runway: $4.2M cash versus $8.8M quarterly cash burn implies insolvency within 6 weeks. Negligible revenue generation ($14K quarterly) fails to offset any operating costs; unsustainable business model.
What is SERA's revenue and growth?
Sera Prognostics, Inc.. reported revenue of $14.0K.
Does SERA pay dividends?
Sera Prognostics, Inc.. does not currently pay dividends.
Where can I find SERA SEC filings?
Official SEC filings for Sera Prognostics, Inc.. (CIK: 0001534969) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is SERA's EPS?
Sera Prognostics, Inc.. has a diluted EPS of $-0.17.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is SERA's fundamental grade?
Based on our AI fundamental analysis in June 2026, Sera Prognostics, Inc.. has a D grade with 95% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is SERA stock overvalued or undervalued?
Valuation metrics for SERA: ROE of -12.4% (sector avg: 15%), net margin of -59,992.9% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is SERA's AI grade for 2026?
Our dual AI analysis gives Sera Prognostics, Inc.. a combined D grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is SERA's free cash flow?
Sera Prognostics, Inc..'s operating cash flow is $-8.8M, with capital expenditures of $8.0K. FCF margin is -62,728.6%.
How does SERA compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -59,992.9% (avg: 12%), ROE -12.4% (avg: 15%), current ratio 2.12 (avg: 2).